Data from ERRα Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer (original) (raw)
Assessment of 25-Year Survival of Women With Estrogen Receptor–Positive/ERBB2-Negative Breast Cancer Treated With and Without Tamoxifen Therapy
Olle Stål
JAMA network open, 2021
View PDFchevron_right
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers
E. Kisanga
Journal of the …, 2003
View PDFchevron_right
Tamoxifen and fenretinide in women with metastatic breast cancer
Maria Merino
Breast Cancer Research and Treatment, 1999
View PDFchevron_right
Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor-Positive Tumors of Tamoxifen-Treated Breast Cancer Patients
Kirsten Nielsen
Clinical Cancer Research, 2007
View PDFchevron_right
Tamoxifen Induces Heparanase Expression in Estrogen Receptor Positive Breast Cancer
Amichay Meirovitz
Clinical Cancer Research, 2007
View PDFchevron_right
Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor‑positive/progesterone receptor‑negative breast cancer
Olle Stål
Molecular and Clinical Oncology, 2020
View PDFchevron_right
What is the role of chemotherapy in estrogen receptor-positive, advanced breast cancer?
Ricardo Caponero
Annals of Oncology, 2009
View PDFchevron_right
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer
Susan Hilsenbeck
Breast Cancer Research and Treatment, 2010
View PDFchevron_right
Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in the Women's Health Initiative Observational Study
Jean Wactawski-wende
Breast Diseases: A Year Book Quarterly, 2013
View PDFchevron_right
Clinical and molecular aspects of breast cancer: Targets and therapies
Glauber Leitao
Biomedicine & Pharmacotherapy, 2018
View PDFchevron_right
BreastDefend Enhances Effect of Tamoxifen in Estrogen Receptor-positive Human Breast Cancer in Vitro and in Vivo
Dr. Isaac Eliaz
2019
View PDFchevron_right
2Q36.3 is Associated with Prognosis for Oestrogen Receptor-Negative Breast Cancer Patients Treated with Chemotherapy
diana torres
2014
View PDFchevron_right
Integration of estrogen and progesterone receptors with pathological and molecular prognostic factors in breast cancer patients
Angela Diblasi
The Journal of Steroid Biochemistry and Molecular Biology, 1998
View PDFchevron_right
Aromatase inhibitors in breast cancer
Manisha Kotadiya, jaydeep savaliya
The American Journal of Geriatric Pharmacotherapy, 2004
View PDFchevron_right
ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
Marcia Inda
Cancers, 2020
View PDFchevron_right
Evaluation of Docetaxel vs. Tamoxifen in Combined Therapies Based on Overall Survival Rate (OSR) Endpoint among Female Breast Cancer Patients
Melanie Tidman
Advances in Cancer Prevention, 2017
View PDFchevron_right
The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer
Geraldine Laven-Law
Nature Medicine, 2021
View PDFchevron_right
Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial
Kirsten Nielsen
European Journal of Cancer, 2014
View PDFchevron_right
Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors
George Notas
Molecular Oncology, 2015
View PDFchevron_right
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction
David Samson
Gynecologic Oncology, 2009
View PDFchevron_right
Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts
Garnet Anderson
Breast Cancer Research, 2018
View PDFchevron_right
Estrogen Plus Progestin Therapy and Breast Cancer in Recently Postmenopausal Women
Garnet Anderson
American Journal of Epidemiology, 2008
View PDFchevron_right
Tamoxifen and Metabolite Concentrations in Serum and Breast Cancer Tissue during Three Dose Regimens in a Randomized Preoperative Trial
E. Kisanga
Clinical Cancer Research, 2004
View PDFchevron_right
Italian Randomized Trial Among Women With Hysterectomy: Tamoxifen and Hormone-Dependent Breast Cancer in High-Risk Women
Peter Boyle
JNCI Journal of the National Cancer Institute, 2003
View PDFchevron_right
Elucidating the role of androgen receptor in breast cancer
Aditi H
Clinical Investigation, 2012
View PDFchevron_right
Biochemical and Molecular Markers in Breast Cancer Patients
Mohammad J Al-Jassani
Annals of Tropical Medicine and Public Health, 2019
View PDFchevron_right
Assessing breast cancer risk
Kathleen Calzone
Postgraduate Medicine, 2004
View PDFchevron_right
Therapeutic Strategies Using the Aromatase Inhibitor Letrozole and Tamoxifen in a Breast Cancer Model
joseph ragaz
JNCI Journal of the National Cancer Institute, 2004
View PDFchevron_right
Figuring Molecular Relapse in Breast Cancer Medicine
Sophie Day
Figure, 2022
View PDFchevron_right
Systemic treatment of early breast cancer-a biological perspective
Sally Greenberg
Journal of Surgical Oncology, 2011
View PDFchevron_right
Clinical relevance of the reappraisal of negative hormone receptor expression in breast cancer
Saudade Andre
SpringerPlus, 2013
View PDFchevron_right
Risk Factors in Breast Cancer Progression and Current Advances in Therapeutic Approaches to Knockdown Breast Cancer
Pervez Anwar
Clinical & Medical Biochemistry, 2018
View PDFchevron_right
Tamoxifen for the Prevention of Breast Cancer: Late Results of the Italian Randomized Tamoxifen Prevention Trial Among Women With Hysterectomy
Peter Boyle
JNCI Journal of the National Cancer Institute, 2007
View PDFchevron_right
Data from Estrogen Receptor-α Phosphorylation at Serine 305, Nuclear p21-Activated Kinase 1 Expression, and Response to Tamoxifen in Postmenopausal Breast Cancer
Olle Stål
2023
View PDFchevron_right
Effect of level of hormone-receptor expression on treatment outcomes of “triple-positive” early-stage breast cancer
Rawan Mustafa
Breast Cancer Research and Treatment, 2020
View PDFchevron_right